Development and validation of a nomogram for local control prediction in lung cancer patients treated with stereotactic body radiation therapy based on clinical, dosimetric, and inflammation-related parameters
Authors:
Open Access
- 10 July 2025
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 1-13
Abstract
The incidence of local recurrence remains noteworthy among lung cancer patients treated with stereotactic body radiation therapy (SBRT). The aim of the study is to identify the risk factors and develop a nomogram for local control (LC) prediction. One hundred fifty-eight primary or metastatic lung cancer patients treated with SBRT were retrospectively analyzed. The clinical, dosimetric and inflammation-related parameters were collected. The Cox regression analysis was performed to determine the independent prognostic factors. A nomogram based on the prognostic factors was established and internally validated using a bootstrap resampling method. The median follow-up time for the whole cohort was 40 months (95% CI: 34–46) and 35.4% of the patients (56/158) experienced local recurrence. The 1-year, 3-year and 5-year LC rates were 97.4%, 85.8% and 76.1%. Multivariate Cox regression analysis revealed that six independent factors were associated with LC, including age, clinical stage, planning target volume (PTV) volume, BED of the prescription dose (BEDPD), lymphocyte count, and neutrocyte count. The bootstrap-corrected C-index of the developed nomogram was 0.745 (95% CI, 0.663–0.793). The time-dependent AUC indicated the nomogram exhibited strong discriminatory capability. Calibration curves demonstrated a good concordance between the predicted and the observed probabilities. The results of decision curve analysis highlighted the clinical utility of the model. Additionally, the high- and low-risk patients were stratified based on the cut-off point from the nomogram (P < 0.0001). A nomogram based on the clinical, dosimetric, and inflammation-related predictors is developed for LC prediction in lung cancer patients treated with SBRT. External validation is required for further confirm its validity.Keywords
Funding Information
- National Natural Science Foundation of China (81602667)
- Guangdong Medical Research Foundation (A2015534, B2023390)
- Basic and Applied Basic Research Foundation of Guangdong Province (2023A1515220015)
- Shantou Medical and Health Science and Technology Planning Project ([2022] 88-7, [2022] 81-1)
This publication has 58 references indexed in Scilit:
- Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapyRadiotherapy and Oncology, 2016
- How to develop a more accurate risk prediction model when there are few eventsBMJ, 2015
- Stereotactic Body Radiotherapy Using a Radiobiology-Based Regimen for Stage I Non–Small-Cell Lung Cancer: Five-Year Mature ResultsJournal of Thoracic Oncology, 2015
- Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2015
- The Tumor Radiobiology of SRS and SBRT: Are More Than the 5 Rs Involved?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancerRadiotherapy and Oncology, 2013
- Consideration of Dose Limits for Organs at Risk of Thoracic Radiotherapy: Atlas for Lung, Proximal Bronchial Tree, Esophagus, Spinal Cord, Ribs, and Brachial PlexusInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- How To Build and Interpret a Nomogram for Cancer PrognosisJournal of Clinical Oncology, 2008
- Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional StudyJournal of Thoracic Oncology, 2007
- X-TileClinical Cancer Research, 2004